海尔生物：公司的盈利能力有望进一步改善

Core Viewpoint - Haier Biomedical indicated that its new production capacity is gradually being released, primarily related to new production lines in Chengdu and Suzhou, which are currently in the ramp-up phase [2] Group 1 - The company expects its profitability to improve further as production stabilizes and the industry normalizes [2] - The enhancement of the company's core competitiveness and the accelerated release of innovative product categories are anticipated to contribute to this improvement [2]